Skip to main content

Industry News

 

Clinical courses

  • New data from a completed phase 3 trial show Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1c (A1C) from baseline after 24 weeks of treatment. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. These data, from the Trulicity AWARD-8 clinical trial, were presented for the first time today at the 2015 International Diabetes Federation (IDF) World Diabetes Congress in Vancouver, Canada.

  • TAKE Solutions launched PV India, a unique pharmacovigilance peer network, organized and managed by one of TAKE’s Life Sciences division, Navitas. At the time when the pharma industry is facing business challenges and the government of India citing delayed regulatory approvals as a primary concern, it is imperative for Pharma companies to arrive at solutions to tackle these problems.

  • Quantum Pharma Plc, the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a further three out-licensing deals in Germany, though Lamda (UK) Limited, Lamda Laboratories SA and Lamda Pharmaceuticals SA (collectively ‘Lamda’), part of its Niche Pharmaceutical division.  These agreements form part of the core strategy for this division.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vasomera (PB1046) Injection for the treatment of cardiomyopathy associated with dystrophinopathies: Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy (XL-dCMP).

  • Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that on November 30, 2015 the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Kevetrin for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye.

  • (NewsVoir); Indian Institute of Technology (IIT), Hyderabad inaugurated the ‘Center for Healthcare Entrepreneurship’, an interdisciplinary center focused on making universal healthcare a reality. The Center was inaugurated by Sri K.T. Rama Rao, Hon'ble Minister for IT & Panchayat Raj, Telangana in the presence of Mr. B V R Mohan Reddy, Chairman, Board of Governors of IIT, Hyderabad, Mr. Avi Nash, Mr. Raj Mashruwala and Prof.UB Desai, Director, IIT Hyderabad.

  • Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd. joined with Roche for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases. The VAP-1 inhibitor is currently in phase II clinical development.

  • To mark World AIDS Day, the Bristol-Myers Squibb Foundation today announced 16 grants totaling $3.5 million for programs in Africa that strengthen HIV services for adolescents and the elderly, raise awareness and access to health care for women co-diagnosed with HIV and breast or cervical cancer, and build community capacity and integrate treatment for HIV/tuberculosis (TB) co-infection.

  • Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) announced today the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) and a Grouped Type II Variation/Extension Application to the European Medicines Agency (EMA) seeking approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease.  Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract that affects approximately 700,000 Americans1 and nearly 250,000 Europeans.2

Subscribe to Industry News